BSI Immune Therapies Summit
Accelerating the next generation of immune therapies across diseases
Hosted by the British Society for Immunology
About the event
The British Society for Immunology (BSI) Immune Therapies Summit is a unique event bringing together sector leaders from industry, academia and clinical spheres to discuss novel approaches and future challenges in immune therapies research. With internationally renowned speakers and an engaging and interactive programme, this inaugural event is an exceptional opportunity to build your cross-sector networks, learn more about current insights and trends in immune therapy development and be part of the conversation to drive forward the next iteration of immunotherapy research for patient benefit.
Who should attend?
The BSI Immune Therapies Summit is aimed at senior leaders from industrial, academic and clinical research settings who are passionate about accelerating immune therapy development and building their cross-sector networks in this field.
Why should you attend?
- Unparalleled and varied networking opportunities with sector leaders from industry, academia and health fields
- Cutting-edge talks and discussions from leading international experts
- Opportunity to take part in holistic, cross-disease discussions on the latest developments across the spectrum of immunotherapy research
- Take part in dynamic focus sessions on how we can accelerate novel approaches to immune therapies research
If you want to be part of the future of immune therapy research, this is the ‘must attend’ event of the year.
Programme
Keynote speaker:
Paul Peter Tak, President & CEO, Candel Therapeutics
Viral immunotherapy: A new therapeutic strategy to induce systemic anti-tumor immunity
Plenary sessions and speakers will include:
Targeting the right immune therapy to the right patient
- Dan Cua, VP Immunology, Janssen Pharmaceutical
- Virginia Pascual, Director, Drukier Institute for Children’s Health
Immune therapies for neurodegeneration
- Marie Kosco-Vilbois, Scientific Advisor, AC Immune
- Michal Schwartz, Professor of Neuroimmunology, Weizmann Institute of Science
Novel approaches to achieving immune tolerance
- Kara Lassen, Head of Immunology, Roche Pharma Research and Early Development
- Georg Schett, Professor of Internal Medicine, University of Erlangen
Cancer vaccines – hope vs hype
- Pippa Corrie, Consultant and Affiliated Associate Professor in Medical Oncology, University of Cambridge
- Kyle Holen, SVP, Head of Development, Therapeutics and Oncology – Research & Development, Moderna
Focus sessions topics include:
- Advances in targeted protein degradation
- Beyond checkpoint inhibitors
- Fibrosis
- Immune ageing
- Immune biomarkers in clinical trials
- Improving on monoclonal antibodies
- Targeting innate immunity
- Targeting tissues
Registration
Register here. Register before Thursday 31 October to benefit from reduced early bird fees.
Sponsorship and exhibition opportunities
There are a number of ways that companies can engage and participate in the BSI Immune Therapies Summit. To learn more about the opportunities available, please contact Becky Dempsey, Events and Corporate Engagement Manager, at b.dempsey@immunology.org.